Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Acute myeloid leukemia (AML) remains a difficult-to-treat malignancy, with long-term overall survival under 30% in adults. Addition of CD33-directed antibody-drug conjugate (ADC) gemtuzumab ozogamicin (GO; Mylotarg), has been shown to improve outcomes and reduce relapse risk in CD33-positive AML [1, 2].
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
